All articles by Irena Maragkou
Irena Maragkou is a Healthcare Researcher for Clinical Trials Arena and Pharmaceutical Technology based in London, UK. Irena previously worked in consulting at Deloitte’s Strategy, M&A and Analytics Department, focusing on projects in the Pharmaceutical and Healthcare Sector. She holds an MSci degree in Neuroscience from UCL.
Insulin pricing in flux as major pharma players take action
With companies announcing price cuts and the government introducing price caps, the US insulin landscape may soon be up for an upheaval.
2022 in review: Tracking the ups and downs of pharma deals
Market volatility due to geopolitical factors hampered pharma M&A in 2022, but recent deals have moved the needle in terms of value.
Rare Disease Spotlight- Oncology therapies dominate the orphan drug landscape
The second edition of the Rare Disease Spotlight series investigates the trends in orphan drug designations across therapy areas over almost 40 years.
Rare Disease Spotlight – Tracing the rise of orphan drug designations over almost 40 years
In the first edition of Pharmaceutical Technology’s series on the FDA’s orphan drug program, we examine how its popularity has grown over the years.
How prepared are US stockpiles for the monkeypox outbreak?
In addition to an approved drug and vaccine, US agencies are negotiating the procurement of a second antiviral to bolster their response.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Qelbree’s recent approval for adults with ADHD highlights need for non-stimulant treatment options
Nonstimulant drugs for attention deficit hyperactivity disorder (ADHD) could address the critical need to mitigate abuse potential.
FDA panel deliberates on Covid-19 booster doses as population immunity wanes
A recent meeting discussed factors driving booster recommendations, and how the flu vaccine experience can guide future strategies.
Neglected disease coalition pushes Pfizer to provide greater Paxlovid access
The Drugs for Neglected Disease initiative (DNDi) claims Pfizer should allow the antiviral’s broader use in low and middle-income countries.
CSL Behring and Grifols to appeal US Border Patrol’s ban on Mexican plasma donations
Regulation on Mexican plasma donations could have detrimental effects on public health.